Publications by authors named "J Le-Rademacher"
Introduction: Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) therapy is the standard of care for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). However, detailed delineation of toxicity data is limited and has not been examined by age. We sought to examine adverse event data in patients receiving R-CHOP from the Cancer and Leukemia Group B (CALGB) 50303 trial to determine if there were differences in grade 3+ toxicities by age cohort or ECOG performance status (PS), and if outcome was impacted by age cohort or toxicity occurrence.
View Article and Find Full Text PDFCorrigendum to 'Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial': [Journal of Thrombosis and Haemostasis Volume 22, Issue 6, June 2024, Pages 1704-1714].
J Thromb Haemost
December 2024
Article Synopsis
- Palbociclib is a common treatment for advanced breast cancer in older adults, but its safety and tolerability for those aged 70 and older is not well established based on current studies.
- A phase 2 study was conducted with 90 participants (median age 74) to assess safety, finding that 75.6% experienced grade 3 or higher adverse events within six months, with the most common being neutropenia.
- The study revealed that older participants (≥75 years) tended to have higher rates of early treatment discontinuations due to adverse events compared to younger older adults (70-74 years), indicating the need for further research on treatment delivery in this age group.
Background: The 8th edition American Joint Committee on Cancer staging system combined anatomic stage (AS) with receptor status and grade to create prognostic stage (PS). PS has been validated in single-institution and cancer registry studies; however, missing human epidermal growth factor receptor 2 (HER2) status and variable treatment and follow-up create limitations.
Objective: Our objective was to compare the relative prognostic ability of PS versus AS to predict survival using breast cancer clinical trial data.